Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Prime Medicine (PRME) Return on Sales (2024 - 2025)

Prime Medicine filings provide 2 years of Return on Sales readings, the most recent being 0.57% for Q4 2025.

  • On a quarterly basis, Return on Sales fell 37.0% to 0.57% in Q4 2025 year-over-year; TTM through Dec 2025 was 0.44%, a 21.0% increase, with the full-year FY2025 number at 0.44%, up 22.0% from a year prior.
  • Return on Sales hit 0.57% in Q4 2025 for Prime Medicine, down from 0.43% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 0.19% in Q4 2024 to a low of 3.68% in Q2 2024.